As we have previously demonstrated in this setting, biomarkers of systemic inflammation are predictive of survival in patients with NSCLC expressing PD-L1 ≥ 50% treated with pembrolizumab [17]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.